Tag: MitraClip

ESC 2019: Two-year findings of MITRA-FR continue to show no prognosis...

At the European Society of Cardiology Congress (ESC 2019; 31 August–4 September, Paris, France), Jean-Francois Obadia (Hopital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation...

Fourth-generation MitraClip receives FDA approval

According to a statement, Abbott has announced it has received US Food and Drug Administration (FDA) approval for the fourth-generation MitraClip heart valve repair...

PASCAL poised to rival MitraClip for safety and efficacy

PASCAL’s (Edwards Lifesciences) safety and efficacy may rival that of MitraClip (Abbott) for the treatment of mitral regurgitation (MR), according to data published in...

MitraClip can be used to treat secondary mitral regurgitation in the...

The US FDA has approved a new indication for percutaneous edge-to-edge repair (MitraClip, Abbott), allowing its use for the reduction of moderate-to-severe or severe...

Draft NICE guidance supports use of percutaneous mitral valve repair

In draft recommendations, England’s National Institute for Health and Care Excellence (NICE) gives the go-ahead for percutaneous edge-to-edge repair (MitraClip, Abbott) for mitral regurgitation...

TCT 2018: Durable tricuspid regurgitation reduction with MitraClip

Data from the TriValve Registry—an international multicentre, retrospective, multidevice, registry evaluating interventional tricuspid repair—indicates that interventional edge-to-edge repair (MitraClip, Abbott) to manage patients with...

TCT 2018: Audience claps as COAPT shows MitraClip reduces HF hospitalisations

Delegates at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21-25 September, San Diego, USA) broke into spontaneous applause after Gregg Stone (Columbia University Medical...

ESC 2018: MitraClip makes “absolutely no difference” for the prognosis...

The first randomised controlled trial to compare percutaneous edge-to-edge repair (MitraClip, Abbott) with medical therapy alone in patients with secondary mitral regurgitation (to heart...

Next-generation of MitraClip approved for use in the USA

Abbott has received approval from the US FDA for a next-generation version of its MitraClip heart valve repair device used to reduce mitral regurgitation....

Location of tricuspid regurgitation predicts procedural success of percutaneous edge-to-edge repair

Supporting the results of previous studies, a new study indicates that percutaneous edge-to-edge repair (MitraClip, Abbott) is a feasible approach for high-risk patients with...

MitraClip becomes first approved device for transcatheter mitral valve repair in...

Abbott has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved its MitraClip device for treatment of people with mitral regurgitation....

Millipede 50mm annuloplasty ring used in first cases

Millipede has announced the successful implantation of its newest 50mm Iris annuloplasty ring, with a transfemoral, transseptal delivery catheter, in a functional mitral regurgitation...

Combining MitraClip mitral valve repair with left atrial appendage occlusion is...

Shingo Kuwata (University Heart Center, Zurich, Switzerland) and others report in Eurointervention that atrial fibrillation is a “frequent comorbidity” in patients with mitral regurgitation...

PCRLV 2016: MitraClip may be “safe and feasible” for treating tricuspid...

A first-in-man study indicates that percutaneous edge-to-edge repair with Abbott Vascular’s MitraClip system is a safe and feasible treatment for tricuspid regurgitation. According to...